Table 1. Patient characteristics.
| Characteristics of patients that received Daratumumab treatment | |
|---|---|
| Variable | Number of patients (%) |
| Total number of patients | 23 (100) |
| Age, mean (range) | 63 (34–82) |
| Gender: female | 6 (29) |
| Myeloma isotype | |
| IgG | 12 (52) |
| IgA | 3 (13) |
| No M-protein, BJ | 8 (35) |
| eGFR Cockcroft-Gault | 85 (14–177) |
| 30–59 (CKD stage 3) | 2 (8%) |
| 15–29 (CKD stage 4) | 1 (4%) |
| <15 (CKD stage 5) | 1 (4%) |
| Bone lesion/s, n (%) | 22 (96) |
| Laboratory values | |
| Creatinine (mmol/L), mean (range) | 80 (36–567) |
| Ca (mmol/L), mean (range) | 2.28 (1.98–2.92) |
| Hb (g/L), mean(range) | 103 (85–141) |
| Albumin (g/L), mean(range) | 33 (16–39) |
| Prior lines of therapy, median (range) | 3 (2–6) |
| Prior treatment | |
| PIs | 23 (100) |
| Bortezomib | 23 (100) |
| Carfilzomib | 3 (13) |
| IMiDs | 23 (100) |
| Lenalidomide | 23 (100) |
| Pomalidomide | 12 (52) |
| Thalidomide | 10 (43) |
| HDT | 12 (52) |
| ASCT | 2 (10) |
Patients received 9 (2–34) infusions of Dara. All patients had exhausted all available treatment options and had advanced MM with resistance to previously used anti-myeloma drugs. The median inclusion age was 63 (34–82) years. CKD = chronic kidney disease, HDT = high dose treatment; ASCT = allogeneic stem cell transplantation.